Dr. Jonathan R. Strosberg on the NETTER-1 Trial and its Impact on Patients With Midgut NETs

Publication
Video
Special ReportsGastrointestinal Cancers: mCRC (Issue 7)
Volume 1
Issue 7

The trial looked at radionuclide therapy Lu-Dotatate in patients with advanced midgut neuroendocrine tumors (NETs), and showed an improvement in overall survival and the reduction of progression or death risk by 79%.

Jonathan R. Strosberg, MD, medical oncologist, Moffitt Cancer Center, discusses the results of the phase III NETTER-1 trial. The trial looked at radionuclide therapy Lu-Dotatate (177Lutetium DOTATATE; Lutathera) in patients with advanced midgut neuroendocrine tumors (NETs), and showed an improvement in overall survival and the reduction of progression or death risk by 79%.

Articles in this issue
Neoadjuvant Therapy Continues to Evolve for Pancreatic Cancer
Neoadjuvant Therapy Continues to Evolve for Pancreatic Cancer
ERCC1 Expression Falls Short as Chemo Biomarker in mCRC
ERCC1 Expression Falls Short as Chemo Biomarker in mCRC
Panitumumab Boosts Overall Survival in Chemorefractory mCRC
Panitumumab Boosts Overall Survival in Chemorefractory mCRC
Dr. Katherine Van Loon on Recognizing Recurrences in Gastrointestinal Cancers
Dr. Katherine Van Loon on Recognizing Recurrences in Gastrointestinal Cancers
Two Options Allows for Treatment Tailoring in Refractory CRC
Two Options Allows for Treatment Tailoring in Refractory CRC
Dr. Jonathan R. Strosberg on the NETTER-1 Trial and its Impact on Patients With Midgut NETs
Dr. Jonathan R. Strosberg on the NETTER-1 Trial and its Impact on Patients With Midgut NETs
Dr. Manish A. Shah on BBI608 in the Treatment Paradigm for Gastrointestinal Cancers
Dr. Manish A. Shah on BBI608 in the Treatment Paradigm for Gastrointestinal Cancers
FOLFOXIRI Bests FOLFOX as Bevacizumab Backbone in mCRC
FOLFOXIRI Bests FOLFOX as Bevacizumab Backbone in mCRC

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content
Panitumumab Boosts Survival in RAS/BRAF Wild-Type Locally Advanced Colon Cancer

Panitumumab Boosts Survival in RAS/BRAF Wild-Type Locally Advanced Colon Cancer

Tony Berberabe, MPH
May 8th 2025
Article

Panitumumab combined with FOLFOX improves survival and reduces recurrence in RAS/BRAF wild-type locally advanced colon cancer.

Read More

LaPelusa’s Journey in the Dynamic Field of GI Oncology

LaPelusa’s Journey in the Dynamic Field of GI Oncology

Jordyn Sava;Michael LaPelusa, MD
May 1st 2024
Podcast

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

Listen

First-in-Human Data Highlight Potential of Intracellular Checkpoint Inhibition in Metastatic Colorectal Cancer

First-in-Human Data Highlight Potential of Intracellular Checkpoint Inhibition in Metastatic Colorectal Cancer

Sabrina Serani
May 3rd 2025
Article

Read More

Unpacking the Latest Research in Gastrointestinal Cancers

Unpacking the Latest Research in Gastrointestinal Cancers

Nichole Tucker;Benjamin L. Schlechter, MD
February 15th 2023
Podcast

In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, discuses new studies in the gastrointestinal cancers space.

Listen

Assessing Risk for JAK Inhibitor Selection in Myelofibrosis

Assessing Risk for JAK Inhibitor Selection in Myelofibrosis

Targeted Oncology Staff
April 25th 2025
Article

In part 1, experts explores how assessing individual risk factors is crucial in selecting the appropriate JAK inhibitor for patients with myelofibrosis.

Read More

SUNLIGHT Trial Defines CRC in the Refractory Setting

SUNLIGHT Trial Defines CRC in the Refractory Setting

Tony Berberabe, MPH
April 24th 2025
Article

Before the emergence of data from the SUNLIGHT trial, there were only 2 options for therapy in advanced colorectal cancer: trifluridine/tipiracil and regorafenib.

Read More